From overall study design and regulatory guidelines to patient access and general time and cost management, clinical trials can quickly become complex and resource intensive.
CENTOGENE is here to help streamline this process for our partners. We provide efficient, effective clinical trial support to help you optimize time and cost, while delivering the highest levels of operational and scientific excellence.
CENTOGENE services in clinical studies span the full spectrum of customized solutions for orphan drug development including in vitro molecular screening, epidemiological studies, biomarker development as well as patient recruitment and identification.
CENTOGENE’s clinical studies yield a rich collection of biological samples. Our highly innovative analytical platforms can analyze genetic, proteomic, transcriptomic and metabolomic data in addition to biochemical and clinical data. We have developed a powerful tool that helps patients by providing them with a quick diagnosis and expert guidance on treatment options.
CENTOGENE’s clinical studies yield a rich collection of biological samples. Our highly innovative analytical platforms can analyze genetic, proteomic, transcriptomic and metabolomic data in addition to biochemical and clinical data. We have developed a powerful tool that helps patients by providing them with a quick diagnosis and expert guidance on treatment options.
CENTOGENE is utilizing the customized solutions for globally dispersed patient populations and including them into our clinical patient identification programs worldwide, that involve patients affected with different rare disorders.
EFRONT is a single visit, multi-centre, non-interventional study that investigates the prevalence of genetic etiologies in Frontotemporal dementia (FTD) by genotyping patients diagnosed/ suspected of FTD.
Learn More
The TRAMmoniTTR study, is a multicenter, epidemiological, longitudinal study to screen and monitor disease progression in patients who carry pathgenic variants of the TTR gene.
Learn More
ROPAD is an international, multicenter, epidemiological, observational study to characterize the genetics of familial Parkinson’s disease. This study is closely linked to a follow-up (LIPAD) study with the University of Lübeck. Both studies aim to establish candidate biomarkers of the disease.
Learn More
By leveraging our proprietary Bio/Databank, multiomic platform, and extensive network of physicians, we help de-risk orphan drug development for our partners by seamlessly identifying the right patients.
We develop new disease models, identify drug targets, and screen compounds to identify potential new drug candidates.
Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET
Contact Us
We aim to reply within 48 hours
